Abstract 2818: PDX model of the enriched pleural effusion from advanced lung cancer patient for testing on targeted drug sensitivity and resistance

Abstract

Abstract Advanced lung cancer of late stage patients is selectively sensitive to available targeted therapeutics and often developing resistance to the early sensitive drug treatment. Surgery tumor tissues are usually not available to establish patient derived xenograft (PDX) models which is critical to evaluate drug sensitivity and resistance. We applied CD45 magnet beads to enrich the tumor cell population from pleural effusion specimens of advanced lung cancer. Seven PDX models were successfully established in this way. Based on genetic profiling of these models, TKI drug related EGFR mutations and ALK fusion were confirmed (EGFR: L858R, T790M, Exon 19 insertion; ALK fusion). Further in vivo efficacy studies were designed to test on multiple drug sensitivity and resistance including Gefitinib, Erlotinib, Ceritinib, Alectinib, AZD9291. Tumor growth inhibition (TGI) were well matched with corresponding gene mutations among the models. In particularly, T790M model was resistant to Erlotinib and quite sensitive for AZD9291. In conclusion, the models established here are very useful to test on potency of many current investigational TKI drugs and provide base for drug resistant model establishment. Citation Format: Feifei Zhang, Ke Wang, Wenhua Xu, Yang Yang, Kedong Ouyang, Shun Lu, Danyi Wen, Taiping Chen. PDX model of the enriched pleural effusion from advanced lung cancer patient for testing on targeted drug sensitivity and resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 2818. doi:10.1158/1538-7445.AM2017-2818